N
Naveris
Biotech & Life Sciences · Waltham, United States · Founded 2017
Delivers innovations in technology with the potential to transform cancer detection, drug development, and clinical trials MoreLess
Naveris is a molecular diagnostics company that develops and commercializes novel blood and saliva tests for the early detection and clinical management of viral-associated cancers. Its flagship product, NavDx, is a blood test that can detect HPV-associated cancers, such as head and neck cancers, at an early stage.
The company's mission is to transform cancer detection, drug development, and clinical trials through its technological innovations. Naveris operates in the biotechnology and healthcare sectors, with a focus on oncology. Its primary clients are healthcare providers, including oncologists and surgeons, who use its diagnostic tools for patient care.
Naveris's business model is centered on the sale of its diagnostic tests. As a commercial-stage life sciences company, it generates revenue by providing these tests to the healthcare market. The company is also involved in drug development and clinical trials, which could represent additional revenue streams or future growth opportunities.
Keywords: molecular diagnostics, cancer detection, blood tests, saliva tests, viral-associated cancers, NavDx, HPV, oncology, biotechnology, life sciences
Company overview
Naveris company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 134
- Open positions
- 15
- Dealroom signal
- 91.4
Valuation & funding
Naveris funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $160M | $160M | CareDx | ↗ |
| EARLY VCOther financing | Jul 2024 | $17M | $167M | Undisclosed | ↗ |
| SERIES AOther financing | Sep 2022 | $33M | $134M | BrightEdge · Gurnet Point Capital · TECHU | ↗ |
| SERIES AOther financing | Dec 2020 | $19M | $76M | Gurnet Point Capital · Sky Ventures Group | — |
| SEEDOther financing | Nov 2019 | $0 | — | Undisclosed | — |
| SPINOUTOther financing | Jan 2017 | UNC Health | — |
Growth signals
Naveris website traffic
Latest recorded traffic for Naveris is 14K monthly website visits, up 204.3% over the last three months. Naveris's team grew 20.7% over the past year.
Hiring
Open positions at Naveris
Current openings linked to this company in Dealroom.
Comparisons
Naveris compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Naveris's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Naveris's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Naveris has talent and traffic
team presence
In the news
Latest news about Naveris
Recent press, funding announcements, and product moves mentioning Naveris — open to read from the original sources.
Market sentiment
What the market is saying about Naveris
An AI-synthesized read of the highest-engagement posts about Naveris on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Naveris’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.